… EGFR mutations, such as the effect of EGFR tyrosine kinase inhibitors (TKIs) or EGFR mutations
… between PD-L1 axis inhibitors and EGFR mutation status. We conducted a review of this …

… EGFR mutations identified that the T790M mutation occurs in 0.7% of all NSCLC cases [20].
Furthermore, the T790M mutation … The T790M mutation sits within the ATP-binding pocket of …

… (EGFR) gene mutations in non-small cell lung cancer (NSCLC… a worldwide overview of EGFR
mutation and submutation (… covariates that influence EGFR mutation status in patients with …

… by EGFR mutations can be associated with resistance to cancer immunotherapy, … EGFR
signal inhibitors should augment the antitumor efficacy. In patients with advanced EGFR-mutated …

… treatments for patients with advanced EGFR‑mutated non‑small cell lung cancer (NSCLC),
and … , EGFR T790M mutation is the primary mechanism of 1st‑ and 2nd‑generation EGFR‑TKI …

… with EGFR-mutated lung cancer naïve for EGFR-TKI, even in the presence of high PD-L1
expression, the efficacy of this ICI could be influenced by TME changes during the EGFR-TKI …

… KRAS mutation and sub-clonal EGFR mutation do not benefit from treatment with EGFR TKIs…
patients with apparent clonal EGFR mutation and sub-clonal KRAS mutation had a median …

… EGFR exon 20–specific (poziotinib, mobocertinib [TAK-788]) TKIs. We also compiled
outcomes of EGFR-A763_Y764insFQEA-mutated lung cancers treated with EGFR TKIs. …

… of those patients with EGFR mutation–positive NSCLC. Although there are five EGFR-TKIs
(… currently available for the treatment of EGFR-mutated lung cancer, the optimal sequence for …

… In addition, most first-line osimertinib-resistant lung cancers do not harbor an obvious, …
In this study, we explored a ubiquitous biological feature of EGFR-mutated lung cancers, the …